Free Trial

NewAmsterdam Pharma Q4 2024 Earnings Report

NewAmsterdam Pharma logo
$23.37 -0.21 (-0.89%)
As of 03/14/2025 04:00 PM Eastern

NewAmsterdam Pharma EPS Results

Actual EPS
-$0.95
Consensus EPS
-$0.48
Beat/Miss
Missed by -$0.47
One Year Ago EPS
N/A

NewAmsterdam Pharma Revenue Results

Actual Revenue
$12.77 million
Expected Revenue
$3.30 million
Beat/Miss
Beat by +$9.47 million
YoY Revenue Growth
N/A

NewAmsterdam Pharma Announcement Details

Quarter
Q4 2024
Time
Before Market Opens

Conference Call Resources

Remove Ads

NewAmsterdam Pharma Earnings Headlines

NewAmsterdam Pharma Company (NAMS) Gets a Buy from Piper Sandler
Nvidia’s CEO: “This Will Be a Multitrillion-Dollar Industry."
If you missed out on the big boom in Nvidia… Listen up, because according to Nvidia's own CEO… Elon Musk’s new technology could help launch an entirely new multitrillion-dollar industry.
See More NewAmsterdam Pharma Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like NewAmsterdam Pharma? Sign up for Earnings360's daily newsletter to receive timely earnings updates on NewAmsterdam Pharma and other key companies, straight to your email.

About NewAmsterdam Pharma

NewAmsterdam Pharma (NASDAQ:NAMS) Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer's disease. NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.

View NewAmsterdam Pharma Profile

More Earnings Resources from MarketBeat